Results 101 to 110 of about 178 (122)

Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Anticancer research, 2013
The majority of alveolar rhabdomyosarcoma (ARMS) are distinguished through the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncoprotein, being generated by a 2;13 chromosomal translocation. This fusion-positive ARMS is the most clinically difficult type of rhabdomyosarcoma.
openaire   +1 more source

Abstract B016: Biochemical mechanisms of PAX3::FOXO1 chromatin invasion in Rhabdomyosarcoma

Cancer Research
Abstract Rhabdomyosarcoma (RMS) is an aggressive pediatric soft tissue cancer, with approximately 350 cases per year in the US. The highly aggressive tumor subtype, Fusion-Positive Rhabdomyosarcoma (FP-RMS) is characterized by chromosomal translocations yielding oncogenic fusion transcription ...
Chamithi Karunanayake, Hayden Statmore, Ehsan Akbari, Alexi Tallan, Frederic Barr, Michael G. Poirier, Benjamin Stanton   +6 more
openaire   +1 more source

Abstract LT006: PAX3::FOXO1-targeting PROTACs in fusion-positive rhabdomyosarcoma

Cancer Research
Abstract Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma. Fusion-positive (FP) RMS typically results in lower survival rates compared to fusion-negative RMS. FP-RMS is characterized by the presence of tumor-specific fusion oncogenes, most commonly PAX3::FOXO1 or PAX7::FOXO1 ...
Nikola Knoll, Kayra Somay, Foram Shah, Purushottam Tiwari, Isabel Frye, Jeffrey Toretsky, Aykut Üren   +6 more
openaire   +1 more source

Abstract 138: UCHL5 and PAX3-FOXO1 resolve replication stress in rhabdomyosarcoma

Cancer Research
Abstract PAX3-FOXO1 positive rhabdomyosarcoma (RMS) is an aggressive pediatric sarcoma with a terrible prognosis. The resultant fusion acts as a chimeric transcription factor, in part remodeling chromatin to inhibit terminal differentiation and maintain cancer cell proliferation.
Amit J. Sabnis, Pushpendra K. Sahu, Yue Pan   +2 more
openaire   +1 more source

PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets

Molecular Cell, 2022
Scott Hiebert, Hillary M Layden, Kristy Stengel   +2 more
exaly  

Differential cell-ECM interaction of rhabdomyosarcoma subtypes regulated by PAX3-FOXO1

Abstract Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma, with two subtypes: Fusion-positive RMS (FPRMS), which has the PAX3-FOXO1 fusion gene, and fusion-negative RMS (FNRMS). Despite their distinct characteristics, treatments mainly rely on conventional chemotherapies without considering these differences. This
Antonios Chronopoulos, Ivan Chavez, Chandra Vemula, Nikhil Mittal, Vic Zamloot, Sangyoon J Han, JinSeok Park   +6 more
openaire   +1 more source

PAX3–FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma

Journal of Pathology, 2017
Stephen M Hewitt, Javed Khan, Bishwanath Chatterjee   +2 more
exaly  

Prognostic value of PAX3/7–FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis

Critical Reviews in Oncology/Hematology, 2015
Taisuke Furuta, Mitsuo Ochi, Tadahiko Kubo   +2 more
exaly  

Small Molecule Binders of the Oncogenic Fusion Transcription Factor PAX3-FOXO1

2023
KOEHLER ANGELA, DOYLE SHELBY, LEIFER BECKY, HENLEY MATTHEW, SCHAEFER BEAT, WACHTEL MARCO   +5 more
openaire   +3 more sources

Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation

International Journal of Biochemistry and Cell Biology, 2011
Andrew D Hollenbach
exaly